H.C. Wainwright analyst Patrick Trucchio has reiterated their bullish stance on QURE stock, giving a Buy rating yesterday.
Patrick Trucchio has given his Buy rating due to a combination of factors that highlight uniQure’s promising future. The company is making significant strides with its AMT-130 program for Huntington’s disease, with regulatory updates and pivotal data expected in 2025. This progress, particularly the FDA’s agreement on an accelerated approval pathway, reduces risks and could fast-track commercialization, making it a transformative moment for the company.
Additionally, uniQure’s broader gene therapy pipeline is advancing, with promising developments in treatments for Fabry disease, refractory mesial temporal lobe epilepsy, and SOD1-ALS. The company’s strong cash position, which extends into the second half of 2027, further supports its valuation, suggesting that the stock is undervalued given the momentum and potential success of its clinical programs.
Trucchio covers the Healthcare sector, focusing on stocks such as Harmony Biosciences Holdings, Sangamo Biosciences, and Beam Therapeutics. According to TipRanks, Trucchio has an average return of -5.0% and a 29.10% success rate on recommended stocks.
In another report released yesterday, Stifel Nicolaus also maintained a Buy rating on the stock with a $30.00 price target.